In recent years there has been a resurgent scientific interest in the psychological effects of psychedelic drugs. Consider the example of recent trials in which psilocybin was administered to people diagnosed with treatment-resistant depression. Those involved reported significantly positive responses even six months later. Such studies point with increasing confidence to the therapeutic potential of psychedelics for treating depression, addiction, anxiety and post-traumatic stress disorder (PTSD), and enhancing palliative care. Amidst this “psychedelic renaissance”, there is one recent study in particular that has grabbed my attention. This study, published in a reputable, peer-reviewed international journal, makes even bolder claims about…
This story continues at The Next Web
Monday 3 February 2020
